Humacyte (NASDAQ:HUMA) Downgraded by Piper Sandler to “Underweight”

Humacyte (NASDAQ:HUMA – Get Rating) was downgraded by Piper Sandler from an “overweight” rating to an “underweight” rating in a report released on Sunday, The Fly reports.

Separately, Zacks Investment Research lowered shares of Humacyte from a “buy” rating to a “hold” rating in a research note on Saturday, April 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $13.65.

NASDAQ HUMA traded up $0.33 on Friday, reaching $5.37. 534,060 shares of the company’s stock traded hands, compared to its average volume of 315,771. The company has a quick ratio of 20.75, a current ratio of 20.75 and a debt-to-equity ratio of 0.40. The stock has a 50-day simple moving average of $6.60 and a 200 day simple moving average of $7.33. Humacyte has a 12 month low of $4.37 and a 12 month high of $17.45.

Humacyte (NASDAQ:HUMA – Get Rating) last posted its quarterly earnings results on Tuesday, March 29th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The company had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.26 million. As a group, analysts expect that Humacyte will post -0.85 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUMA. Penserra Capital Management LLC bought a new stake in shares of Humacyte during the 4th quarter valued at about $25,000. Citigroup Inc. bought a new stake in Humacyte during the third quarter valued at about $47,000. Dixon Hughes Goodman Wealth Advisors LLC bought a new stake in Humacyte during the first quarter valued at about $48,000. Bank of America Corp DE grew its holdings in Humacyte by 96.7% during the fourth quarter. Bank of America Corp DE now owns 6,887 shares of the company’s stock valued at $51,000 after purchasing an additional 3,385 shares during the period. Finally, Teacher Retirement System of Texas bought a new stake in Humacyte during the fourth quarter valued at about $73,000. 9.25% of the stock is currently owned by hedge funds and other institutional investors.

About Humacyte (Get Rating)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).

Featured Stories